Related Experiment Video
Updated: Aug 10, 2026
13:36
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Next generation DNA vaccines for HIV-1
J D Boyer1, Michael Chattergoon, Karuppiah Muthumani
1Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Journal of Liposome Research
|February 27, 2003
Summary
First-generation HIV-1 plasmid vaccines showed good tolerance but low CTL responses. Enhancements using B7 costimulatory molecules and cytokines like IL-12 and IL-15 significantly boosted immune responses for more potent vaccine development.
Area of Science:
- Immunology
- Vaccinology
- Molecular Biology
Background:
- First-generation HIV-1 plasmid vaccines were well-tolerated but elicited suboptimal cytotoxic T lymphocyte (CTL) responses.
- Improving vaccine potency is crucial for effective prophylaxis and therapy.
Purpose of the Study:
- To enhance the immune response of plasmid vaccines.
- To investigate the efficacy of engineered B7 costimulatory molecules and cytokines as adjuvants.
Main Methods:
- Utilized RNA-optimized constructs (pGag, pEnv) for improved expression.
- Incorporated engineered B7.1 and B7.2 costimulatory molecules, including gene swaps and deletions.
- Explored the use of interleukin-12 (IL-12) and interleukin-15 (IL-15) as plasmid vaccine adjuvants.
Main Results:
- RNA-optimized constructs showed 20-100 fold higher expression than first-generation vectors.
- Engineered B7 costimulatory molecules, particularly B7.2, significantly enhanced CD8 effector cell responses (CTL, ICC, Elispot).
- IL-12 and IL-15 demonstrated effectiveness as plasmid vaccine adjuvants, with IL-15 promoting T cell expansion independently of T cell help.
Conclusions:
- Both costimulatory signals and cytokine adjuvants can be engineered to significantly improve plasmid vaccine potency.
- These findings offer a promising strategy for developing more effective vaccines for HIV prevention and treatment.
Related Concept Videos
00:36Viral Mutations
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:26Size and Structure of Viral Genomes
Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...